Research and experimental development on natural sciences and engineering
EUROFINS BIOPHARMA PRODUCT TESTING NORWAY AS
Revenue 2024
NOK 1.2m
Operating profit
NOK 452,000
Equity
NOK 696,000
Incorporated
2023
Share capital
NOK 30,000
Key figures · 2024
Current ratio
2.08
Equity ratio
51.8%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | 36.9% | |
| Net margin (%%) | 28.4% | |
| Return on assets (%%) | 33.7% | |
| Likviditet | ||
| Current ratio | 2.08 | |
| Working capital | 696k | |
| Soliditet | ||
| Equity ratio (%%) | 51.8% | |
| Debt-to-equity ratio | 0.93 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.